Exploring natural products as a source for antidiabetic lead compounds and possible lead optimization

Current Topics in Medicinal Chemistry

Volumn 16, Issue 23, 2016, Pages 2549-2561

  Khalaf, Reema Abu ^a  

^a AL ZAYTOONAH UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Aldose reductase; Antidiabetic; Dipeptidyl peptidase IV; Molecular docking; Natural lead; Peroxisome proliferatoractivated receptor gamma; Protein tyrosine phosphatase 1B; glucosidase

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALDOSE REDUCTASE INHIBITOR; ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BERBERINE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FRUCTOSE OLIGOSACCHARIDE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; ISOQUINOLINE DERIVATIVE; PALINURIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; SALACINOL; TOCOPHEROL DERIVATIVE; UNCLASSIFIED DRUG; XANTHENE DERIVATIVE; BIOLOGICAL PRODUCT;

ANTIDIABETIC ACTIVITY; ARTICLE; CASTANOSPERMUM; COMPUTER MODEL; COPTIS CHINENSIS; CUCURBITA PEPO; DIABETES MELLITUS; HUMAN; MOLECULAR DOCKING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PISTACIA; STRUCTURE ACTIVITY RELATION; VITEX NEGUNDO; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; DRUG DEVELOPMENT; ENZYMOLOGY; ISOLATION AND PURIFICATION; METABOLISM;

BIOLOGICAL PRODUCTS; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; DRUG DISCOVERY; HYPOGLYCEMIC AGENTS;

EID: 84979232563     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026616666160414123602     Document Type: Article

References (112)

1. Newman, D.J.; Cragg, G.M. Natural Products as Sources of New Drugs over the 30 Years from 1981 to 2010. J. Nat. Prod., 2012, 75, 311-335.
2. Ji, H.F.; Li, X.J.; Zhang, H.Y. Natural products and drug discovery can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? Embo. Reports, 2009, 10, 194-200.
3. Harvey, A. Natural products in drug discovery. Drug Discov. Today, 2008, 13, 894-901.
4. Kingston, D.G.I. Modern Natural Products Drug Discovery and Its Relevance to Biodiversity Conservation. J. Nat. Prod., 2011, 74, 496-511.
5. Chin, Y.W.; Balunas, M.J.; Chai, H.B.; Kinghorn, A.D. Drug discovery from natural sources. AAPS J., 2006, 8, E239-E253.
6. Hong, J.Y. Role of natural product diversity in chemical biology. Curr. Opin. Chem. Biol., 2011, 15, 350-354.
7. Gu, J.; Gui, Y.; Chen, L.; Yuan, G.; Lu, H.Z.; Xu, X. Use of Natural Products as Chemical Library for Drug Discovery and Network Pharmacology. PLOS ONE, 2013, 8(4), 1-10.
8. Mishra, B.B.; Tiwari, V.K. Natural products: An evolving role in future drug discovery. Eur. J. Med. Chem., 2011, 46, 4769-4807.
9. Cragg, G.M.; Newman, D.J. Natural products: A continuing source of novel drug leads. Biochim. Biophys. Acta, 2013, 1830, 3670-3695.
10. Chen, J.; Li, W.; Yao, H.; Xu, J. Insights into drug discovery from natural products through structural modification. Fitoterapia, 2015, 103, 231-241.
11. International Diabetes Federation. Diabetes Atlas, 6th ed.; 2013.
12. Boyle, J.P.; Thompson, T.J.; Gregg, E.W.; Barker, L.E.; Williamson, D.F. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul. Health Metr., 2010, 8, 29.
13. Liang, K.; Sun, Y.; Li, W.J.; Zhang, X.P.; Li, C.Q.; Yang, W.F.; Ma, Z.Q.; Ma, A.X.; Zheng, H.Z.; Song, J.; Lin, P.; Hou, X.G.; Chen, L. Diagnostic efficiency of hemoglobin A1c for newly diagnosed diabetes and prediabetes in community based Chinese adults aged 40 years or older. Diabetes Technol. Ther., 2014, 16, 853-857.
14. Mukai, N.; Doi, Y.; Ninomiya, T.; Hirakawa, Y.; Nagata, M.; Yoshida, D.; Hata, J.; Fukuhara, M.; Nakamura, U.; Kitazono, T.; Kiyohara, Y. Trends in the prevalence of type 2 diabetes and prediabetes in community-dwelling Japanese subjects: the Hisayama study. J. Diabetes Investig., 2014, 5, 162-169.
15. Wise, J. A third of adults in England have "prediabetes", study says. BMJ, 2014, 348, g3791.
16. Gujral, U.P.; Narayan, K.M.; Pradeepa, R.G.; Deepa, M.; Ali, M.K.; Anjana, R.M.; Kandula, N. R.; Mohan, V.; Kanaya, A.M. Comparing type 2 diabetes, prediabetes, and their associated risk factors in Asian Indians in India and in the U.S.: the CARRS and MASALA studies. Diabetes Care, 2015, 38, 1312-1318.
17. Mota, M.; Popa, S.G.; Mota, E.; Mitrea, A.; Catrinoiu, D., Cheta, D.M.; Guja, C.; Hancu, N.; Ionescu-Tirgoviste, C.; Lichiardopol, R.; Mihai, B.M.; Popa, A.R.; Zetu, C.; Bala, C.G.; Roman, G.; Serafinceanu, C.; Serban, V.; Timar, R.; Veresiu, I.A.; Vlad, A.R. Prevalence of diabetes mellitus and prediabetes in the adult Romanian population: PREDATORR study. J. Diabetes, 2015, doi: 10.1111/1753-0407.12297.
18. Bharatam, P.V.; Patel, D.S.; Adane, L.; Mittal, A.; Sundriyal, S. Modeling and informatics in designing anti-diabetic agents. Curr. Pharm. Des., 2007, 13, 3518-3530.
19. Waku, T.; Shiraki, T.; Oyama, T.; Maebara, K.; Nakamori, R.; Morikawa, K. The nuclear receptor PPARγ individually responds to serotonin-and fatty acid-metabolites. EMBO J., 2010, 29, 3395-3407.
20. Bharti, S.K.; Krishnan, S.; Kumar, A.; Rajak, K.K.; Murari, K.; Bharti, B.K.; Gupta, A.K. Antidiabetic activity and molecular docking of fructooligosaccharides produced by Aureobasidium pullulans in poloxamer-407-induced T2DM rats. Food Chem., 2013, 136, 813-821.
21. Bharti, S.K.; Krishnan, S.; Kumar, A.; Rajak, K.K.; Murari, K.; Bharti, B.K.; Gupta, A.K. Antihyperglycemic activity with DPP-IV inhibition of alkaloids from seed extract of Castanospermum australe: investigation by experimental validation and molecular docking. Phytomedicine, 2012, 20, 24-31.
22. Combs, A.P. Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. J. Med. Chem., 2010, 53, 2333-2344.
23. Bhandari, M.R.; Nilubon, J.A.; Gao, H.; Kawabata, J. α-Glucosidase and α-amylase inhibitory activities of Nepalese medicinal herb Pakhanbhed (Bergenia ciliata, Haw.). Food Chem., 2008, 106(1), 247-252.
24. Krentz, A.J.; Bailey, C.J. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs, 2005, 65, 385-411.
25. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications, Nature, 2001, 414, 813-820.
26. Kawanishi, K.; Ueda, H.; Moriyasu, M. Aldose reductase inhibitors from the nature, Curr. Med. Chem., 2003, 10, 1353-1374.
27. Sutton, J.M.; Clark, D.E.; Dunsdon, S.J.; Fenton, G.; Fillmore, A.; Harris, N.V.; Higgs, C.; Hurley, C.A.; Krintel, S.L.; MacKenzie, R.E.; Duttaroy, A.; Gangl, E.; Maniara, W.; Sedrani, R.; Namoto, K.; Ostermann, N.; Gerhartz, B.; Sirockin, F.; Trappe, J.; Hassiepen, U.; Baeschlin, D.K. Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett., 2012, 22(3), 1464-1468.
28. Heinrich, M.; Barnes, J.; Gibbons, S.; Williamson, E.M. Fundamentals of pharmacognosy and phytotherapy. Edinburgh: Churchill Livingstone; 2004.
29. Pant, S.; Samant, S.S. Ethanobotanical observation in the Momaula Reserve Forest of Koumoun, West Himalaya, India. Ethanobotanical Leaflets, 2010, 1493.
30. Ahmad, N.S.; Waheed, A.; Farman, M.; Qayyum, A. Analgesic and antiinflammatory effects of Pistacia integerrima extracts in mice. J. Ethnopharmacol., 2010, 129(2), 250-253.
31. Hou, W.; Li, Y.; Zhang, Q.; Wei, X.; Peng, A.; Chen, L.; Wei, Y. Triterpene acids isolated from Lagerstroemia speciosa leaves as alpha-glucosidase inhibitors. Phytother. Res., 2009, 23, 614-618.
32. Mbaze, L.M.; Poumale, H.M.; Wansi, J.D.; Lado, J.A.; Khan, S.N.; Iqbal, M.C.; Ngadjui, B.T.; Laatsch, H. alpha-Glucosidase inhibitory pentacyclic triterpenes from the stem bark of Fagara tessmannii (Rutaceae). Phytochemistry, 2007, 68(5), 591-595.
33. Kumar, D.; Shah, V.; Ghosh, R.; Pal, B.C. A new triterpenoid saponin from Glinus oppositifolius with α-glucosidase inhibitory activity. Nat. Prod. Res., 2013, 27(7), 624-629.
34. Benalla, W.; Bellahcen, S.; Bnouham, M. Antidiabetic medicinal plants as a source of alpha glucosidase inhibitors. Curr. Diabetes Rev., 2010, 6, 247-254.
35. Uddin, G.; Rauf, A.; Al-Othman, A.M.; Collina, S.; Arfan, M.; Ali, G.; Khan, I. Pistagremic acid, a glucosidase inhibitor from Pistacia integerrima. Fitoterapia, 2012, 83, 1648-1652.
36. Mohan, S.; Pinto, B.M. Zwitterionic glycosidase inhibitors: salacinol and related analogues. Carbohydr. Res., 2007, 342(12-13), 1551-1580.
37. Xie, W.; Tanabe, G.; Xu, J.; Wu, X.; Morikawa, T.; Yoshikawa, M.; Muraoka, O. Research Progress of Synthesis and Structureactivity Relationship Studies on Sulfonium-type α-glucosidase Inhibitors Isolated from Salacia Genus Plants. Mini-Rev. Org. Chem., 2013, 10(2), 141-159.
38. Morikawa, T.; Akaki, J.; Ninomiya, K.; Kinouchi, E.; Tanabe, G.; Pongpiriyadacha, Y.; Yoshikawa, M.; Muraoka, O. Salacinol and related analogs: new leads for type 2 diabetes therapeutic candidates from the Thai traditional natural medicine Salacia chinensis. Nutrients, 2015, 7(3), 1480-1493.
39. Nakamura, S.; Takahira, K.; Tanabe, G.; Morikawa, T.; Sakano, M.; Ninomiya, K.; Yoshikawa, M.; Muraoka, O.; Isao Nakanishi, I. Docking and SAR studies of salacinol derivatives as α-glucosidase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(15), 4420-4423.
40. You, Q.; Chen, F.; Wang, X.; Jiang, Y.; Lin, S. Anti-diabetic activities of phenolic compounds in muscadine against alphaglucosidase and pancreatic lipase. LWT-Food Sci. Technol., 2012, 46(1), 164-168.
41. Islam, M.N.; Jung, H.A.; Sohn, H.S.; Kim, H.M.; Choi, J.S. Potent α-glucosidase and protein tyrosine phosphatase 1B inhibitors from Artemisia capillaris, Arch. Pharmacal. Res., 2013, 36, 542-552.
42. Seo, E.J.; Curtis-Long, M.J.; Lee, B.W.; Kim, H.Y.; Ryu, Y.B.; Jeong, T.S.; Lee, W.S.; Park, K.H. Xanthones from Cudrania tricuspidata displaying potent alpha-glucosidase inhibition. Bioorg. Med. Chem. Lett., 2007, 17(23), 6421-6424.
43. Liu, Y.; Ke, Z.; Cui, J.; Chen, W.H.; Ma, L.; Wang, B. Synthesis, inhibitory activities, and QSAR study of xanthone derivatives as α-glucosidase inhibitors. Bioorg. Med. Chem., 2008, 16, 7185-7192.
44. Lambeir, A.M.; Durinx, C.; Scharpé, S.; De Meester, I. Dipeptidylpeptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci., 2003, 40, 209-294.
45. Al-Masri, I.M.; Mohammad, M.K.; Taha, M.O. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J. Enzyme Inhib. Med. Chem., 2009, 24(5), 1061-1066.
46. Srinivasan, P.; Sudha, A.; Manikandan, R.; Arulvasu, C. Molecular Docking Studies of 1, 2 Disubstituted Idopyranose from Vitex Negundo with Anti-diabetic Activity of Type 2 Diabetes. Intl. J. Pharma Bio Sci., 2011, 2(1), 68-83.
47. Bharti, S.K.; Kumar, A.; Sharma, N.K.; Prakash, O.; Jaiswal, S.K.; Krishnan, S.; Gupta, A.K.; Kumar, A. Tocopherol from seeds of Cucurbita pepo against diabetes: Validation by in vivo experiments supported by computational docking. J. Formos. Med. Assoc., 2013, 112, 676-690.
48. Tontonoz, P.; Spiegelman, B.M. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem., 2008, 77, 289-312.
49. Na, H.K.; Surh, Y.J. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem. Pharmacol., 2003, 66, 1381-1391.
50. Heikkinen, S.; Auwerx, J.; Argmann, C.A. PPARgamma in human and mouse physiology. Biochim. Biophys. Acta, 2007, 1771, 999-1013.
51. Wang, L.; Waltenberger, B.; Pferschy-Wenzig, E.M.; Blunder, M.; Liu, X.; Malainer, C.; Blazevic, T.; Schwaiger, S.; Rollinger, J.M.; Heiss, E.H.; Schuster, D.; Kopp, B.; Bauer, R.; Stuppner, H.; Dirsch, V.M.; Atanasov, A.G. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem. Pharmacol., 2014, 92, 73-89.
52. Shin, D.W.; Kim, S.N.; Lee, S.M.; Lee, W.; Song, M.J.; Park, S.M.; Lee, T.R.; Baik, J.H.; Kim, H.K.; Hong, J.H.; Noh, M. (-)-Catechin promotes adipocyte differentiation in human bone marrow mesenchymal stem cells through PPAR gamma transactivation. Biochem. Pharmacol., 2009, 77, 125-133.
53. Dang, Z.C.; Audinot, V.; Papapoulos, S.E.; Boutin, J.A.; Lowik, C.W. Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. J. Biol. Chem., 2003, 278, 962-967.
54. Fang, F.; Kang, Z.; Wong, C. Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors. Mol. Nutr. Food Res., 2010, 54, 345-352.
55. Isa, Y.; Miyakawa, Y.; Yanagisawa, M.; Goto, T.; Kang, M.S.; Kawada, T.; Morimitsu, Y.; Kubota, K.; Tsuda, T. 6-Shogaol and 6-gingerol, the pungent of ginger, inhibit TNF-alpha mediated downregulation of adiponectin expression via different mechanisms in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun., 2008, 373(3), 429-434.
56. Zoechling, A.; Liebner, F.; Jungbauer, A. Red wine: a source of potent ligands for peroxisome proliferator-activated receptor gamma. Food Funct., 2011, 2, 28-38.
57. Mueller, M.; Lukas, B.; Novak, J.; Simoncini, T.; Genazzani, A.R.; Jungbauer, A. Oregano: a source for peroxisome proliferatoractivated receptor gamma antagonists. J. Agr. Food Chem., 2008, 56, 11621-11630.
58. Rau, O.; Wurglics, M.; Paulke, A.; Zitzkowski, J.; Meindl, N.; Bock, A.; Dingermann, T.; Abdel-Tawab, M.; Schubert-Zsilavecz, M. Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator activated receptor gamma. Planta Med., 2006, 72(10), 881-887.
59. Christensen, K.B.; Jorgensen, M.; Kotowska, D.; Petersen, R.K.; Kristiansen, K.; Christensen, L.P. Activation of the nuclear receptor PPARgamma by metabolites isolated from sage (Salvia officinalis L.). J. Ethnopharmacol., 2010, 132, 127-133.
60. Hotta, M.; Nakata, R.; Katsukawa, M.; Hori, K.; Takahashi, S.; Inoue, H. Carvacrol, a component of thyme oil, activates PPARalpha and gamma and suppresses COX-2 expression. J. Lipid Res., 2010, 51, 132-139.
61. Itoh, T.; Fairall, L.; Amin, K.; Inaba, Y.; Szanto, A.; Balint, B.L.; Nagy, L.; Yamamoto, K.; Schwabe, J.W. Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat. Struct. Mol. Biol., 2008, 15, 924-931.
62. Puhl, A.C.; Bernardes, A.; Silveira, R.L.; Yuan, J.; Campos, J.L.; Saidemberg, D.M.; Palma, M.S.; Cvoro, A.; Ayers, S.D.; Webb, P.; Reinach, P.S.; Skaf, M.S.; Polikarpov, I.. Mode of peroxisome proliferator-activated receptor gamma activation by luteolin. Mol. Pharmacol., 2012, 81, 788-799.
63. Liberato, M.V.; Nascimento, A.S.; Ayers, S.D.; Lin, J.Z.; Cvoro, A.; Silveira, R.L.; Leandro Martinez, L.; Souza, P.C.T.; Saidemberg, D.; Deng, T.; Amato, A.A.; Togashi, M.; Hsueh, W.A.; Phillips, K.; Palma, M.S.; Skaf, F.A.R.M.S.; Webb, P.; Polikarpov, I. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) gamma activators and pan-PPAR partial agonists. PLOS ONE, 2012, 7(5), e36297.
64. Nolte, R.T.; Wisely, G.B.; Westin, S.; Cobb, J.E.; Lambert, M.H.; Kurokawa, R.; Rosenfeld, M.G.; Willson, T.M.; Glass, C.K.; Milburn, M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature, 1998, 395, 137-143.
65. Rao, V.R.S.; Suresh, G.; Babu, K.S.; Raju, S.S.; Vishnu Vardhan, M.V.P.S.; Ramakrishna, S.; Rao, J.M. Novel dimeric amide alkaloids from Piper chaba Hunter: isolation, cytotoxic activity, and their biomimetic synthesis. Tetrahedron, 2011, 67(10), 1885-1892.
66. Rao, V.R.; Muthenna, P.; Shankaraiah, G.; Akileshwari, C.; Babu, K.H.; Suresh, G.; Babu, K.S.; Rotte Sateesh Kumar, C.; Prasad, K.R.; Yadav, P.A.; Petrash, J.M.; Reddy, G.B.; Rao, J.M. Synthesis and biological evaluation of new piplartine analogues as potent aldose reductase inhibitors (ARIs). Eur. J. Med. Chem., 2012, 57, 344-361.
67. Muthenna, P.; Suryanarayana, P.; Gunda, S.K.; Petrash, J.M.; Reddy, G.B. Inhibition of aldose reductase by dietary antioxidant curcumin: Mechanism of inhibition, specificity and significance. FEBS Lett., 2009, 583(22), 3637-3642.
68. Abdallah, H.M.; Salama, M.M.; Abd-elrahman, E.H.; El-Maraghy, S.A. Antidiabetic activity of phenolic compounds from Pecan bark in streptozotocin-induced diabetic rats. Phytochem. Lett., 2011, 4, 337-341.
69. Jung, H.A.; Islam, M.N.; Lee, C.M.; Oh, S.H.; Lee, S.; Jung, J.H.; Choi, J.S. Kinetics and molecular docking studies of an antidiabetic complication inhibitor fucosterol from edible brown algae Eisenia bicyclis and Ecklonia stolonifera. Chem. Biol. Interact., 2013, 206, 55-62.
70. Kamerlin, S.C.; Rucker, R.; Boresch, S. A molecular dynamics study of WPD-loop flexibility in PTP1B. Biochem. Biophys. Res. Commun., 2007, 356, 1011-1016.
71. Zinker, B.A.; Rondinone, C.M.; Trevillyan, J.M.; Gum, R.J.; Clampit, J.E.; Waring, J.F.; Xie, N.; Wilcox, D.; Jacobson, P.; Frost, L.; Kroeger, P.E.; Reilly, R.M.; Koterski, S.; Opgenorth, T.J.; Ulrich, R.G.; Crosby, S.; Butler, M.; Murray, S.F.; McKay, R.A.; Bhanot, S.; Monia, B.P.; Jirousek, M.R. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. USA, 2002, 99, 11357-11362.
72. González-Rodríguez, A.; Más-Gutierrez, J.A.; Mirasierra, M.; Fernandez-Pérez, A.; Lee, Y.J.; Ko, H.J.; Kim, J.K.; Romanos, E.; Carrascosa, J.M.; Ros, M.; Vallejo, M.; Rondinone, C.M.; Valverde, A.M. Essential role of protein tyrosine phosphatase 1 B in obesity-induced inflammation and peripheral insulin resistance during aging. Aging Cell, 2012, 11, 284-296.
73. Koren, S.; Fantus, I.G. Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus. Best Pract. Res. Clin. Endocrinol. Metab., 2007, 21, 621-640.
74. Wang, L.J.; Jiang, B.; Wu, N.; Wang, S.Y.; Shi, D.Y. Natural and semisynthetic protein tyrosine phosphatase 1B (PTP1B) inhibitors as anti-diabetic agents. RSC Adv., 2015, 5, 48822-48834.
75. Jung, H.A.; Yoon, N.Y.; Bae, H.J.; Min, B.S.; Choi, J.S. Inhibitory activities of the alkaloids from Coptidis Rhizoma against aldose reductase. Arch. Pharm. Res., 2008, 31, 1405-1412.
76. Sun, J.; Ma, J.S.; Jin, J.; Wang, H.S.; Wen, Q.H.; Zhang, H.G.; Zhou, Q.L. Qualitative and quantitative determination of the main components of huanglianjiedu decoction by HPLC-UV/MS. Yao Xue Xue Bao, 2006, 41, 380-384.
77. Tang, L.Q.; Wei, W.; Chen, L.M.; Liu, S. Effects of berberine on diabetes induced by alloxan and a high-fat/ high-cholesterol diet in rats. J. Ethnopharmacol., 2006, 108, 109-115.
78. Huang, C.; Zhang, Y.; Gong, Z.; Sheng, X.; Li, Z.; Zhang, W.; Qin, Y. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARγ pathway. Biochem. Biophys. Res. Commun., 2006, 348, 571-578.
79. Choi, J.S.; Ali, M.Y.; Jung, H.A.; Oh, S.H.; Choi, R.J.; Kim, E.J. Protein tyrosine phosphatase 1 B inhibitory activity of alkaloids from Rhizoma Coptidis and their molecular docking studies. J. Ethnopharmacol., 2015, 171, 28-36.
80. Keri, R.S.; Budagumpi, S.; Pai, R.K.; Balakrishna, R.G. Chromones as a privileged scaffold in drug discovery: A review. Eur. J. Med. Chem., 2014, 78, 340-374.
81. Doble, B.W.; Woodgett, J.R. GSK-3: Tricks of the trade for a multi-tasking kinase. J. Cell Sci., 2003, 116, 1175-1186.
82. Mukai, F.; Ishiguro, K.; Sano, Y.; Fujita, S.C. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β. J. Neurochem., 2002, 81, 1073-1083.
83. McManus, E.J.; Sakamoto, K.; Armit, L.J.; Ronaldson, L.; Shapiro, N.; Marquez, R.; Alessi, D.R. Role that phosphorylation of GSK3 plays in insulin and Wnt signaling defined by knock in analysis. Embo. J., 2005, 24, 1571-1583.
84. Meijer, L.; Thunnissen, A.M.W.H.; White, A.W.; Garnier, M.; Nikolic, M.; Tsai, L.H.; Walter, J.; Cleverley, K.E.; Salinas, P.C.; Wu, Y.Z.; Biernat, J.; Mandelkow, E.M.; Kim, S.H.; Pettit, G.R. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol., 2000, 7(1), 51-63.
85. Alonso, G.D.; Dorronsoro, D.I.; Martinez, G.A.; Panizo, dPG.; Fuertes, H.A.; Perez Puerto, M.J.; Martin, A.E.; Perez, N.D.; Medina, P.M. PCT Int. Appl., 2005, WO 2005054221.
86. Hamann, M.T.; Alonso,D.; Martin-Aparicio, E.; Fuertes, A.; Perez-Puerto, J.; Castro, A.; Morales, S.; Navarro, M.L.; del Monte-Millan, M.; Medina, M.; Pennaka, H.; Balaiah, A.; Peng, J.; Cook, J.; Wahyuono, S.; Martinez, A. GSK-3 Inhibitory activity and SAR studies of the manzamine alkaloids. Potential for Alzheimer’s disease. J. Nat. Prod., 2007, 70, 1397-1405.
87. Mudit, M.; Khanfar, M.; Muralidharan, A.; Thomas, S.; Shah, G.V.; van Soest, R.W.M.; El Sayed, K.A. Discovery, design, and synthesis of anti-metastatic lead phenylmethylene hydantoins inspired by marine natural products. Bioorg. Med. Chem., 2009, 17, 1731-1738.
88. Khanfar, M.A.; Abu Asal, B.; Mudit, M.; Kaddoumi, A.; El Sayed, K.A. The marine natural-derived inhibitors of glycogen synthase kinase-3phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling. Bioorg. Med. Chem., 2009, 17, 6032-6039.
89. Stewart, P.M.; Worwood, C.B.; Walker, B.R. Steroid hormones and hypertension: The cortisol-cortisone shuttle. Steroids, 1993, 58, 614-620.
90. Davani, B.; Khan, A.; Hult, M.; Mårtensson, E.; Okret, S.; Efendic, S.; Jörnvall, H.; Oppermann, U.C.T. J. Biol. Chem., 2000, 275, 34841-34844.
91. Stulnig, T.M.; Waldhaeusl, W. 11β-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes. Diabetologia, 2004, 47, 1-11.
92. Deng, X.; Shen,Y.; Yang, J.; He, J.; Zhao, Y.; Peng, L.Y.; Leng, Y.; Zhao, Q.S. Discovery and structure-activity relationships of ent-Kaurene diterpenoids as potent and selective 11b-HSD1 inhibitors: Potential impact in diabetes. Eur. J. Med. Chem., 2013, 65, 403-414.
93. Collier J.J.; Scott D.K. Sweet changes; Glucose Homeostasis can be altered by manipulating genes controlling hepatic glucose metabolism. Mol. Endocrinol., 2004, 18, 1051-1063.
94. Angadi, K.K.; Gundampati, R.K.; Jagannadham, M.V.; Kandru, A. Molecular docking studies of guggultetrol from Nymphaea pubescens with target glucokinase (GK) related to type-II Diabetes. J. App. Pharm. Sci., 2013, 3(2), 127-131.
95. Mahendran, G.; Manoj, M.; Rajendra Prasad, K.J.; Narmatha Bai, V. Evaluation of anti-inflammatory and anti-nociceptive activity of xanthones from Swertia corymbosa (Griseb.) Wight ex C.B. Clarke. Int. J. Pharm. Pharm. Sci., 2013, 5(3), 523-529.
96. Mahendran, G.; Manoj, M.; Murugesh, E.; Sathish Kumar, R.; Shanmughavel, P.; Rajendra Prasad, K.J.; Narmatha Bai, V. In vivo anti-diabetic, antioxidant and molecular docking studies of 1,2,8-trihydroxy-6-methoxy xanthone and 1,2-dihydroxy-6-methoxyxanthone-8-O-D-xylopyranosyl isolated from Swertia corymbosa. Phytomedicine, 2014, 21, 1237-1248.
97. Hayes, J.D.; Dinkova-Kostova, A.T. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci., 2014, 39, 199-218.
98. Turpaev, K.T. Keap1-Nrf2 signaling pathway: mechanisms of regulation and role in protection of cells against toxicity caused by xenobiotics and electrophiles. Biochemistry, 2013, 78, 147-166.
99. Jiménez-Osorio, A.S.; González-Reyes, S.; Pedraza-Chaverri, J. Natural Nrf2 activators in diabetes. Clin. Chim. Acta, 2015, 448, 182-192.
100. Torre, P.; Reboli, A.C. Anidulafungin: a new echinocandin for candidal infections. Expert Rev. Anti-Infect. Ther., 2007, 5(1), 45-52.
101. Wolfson, W. Leapin’ Lizards: Amylin Targets Diabetes and Obesity via Incretins. Chem. Biol., 2007, 14(3), 235-236.
102. Barnett, A. Exenatide. Expert Opin. Pharmacother., 2007, 8(15), 2593-2608.
103. Cvetkovic, R.S.; Plosker, G.L. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs, 2007, 67, 935-954.
104. Ehrenkranz, J.R.L.; Lewis, N.G.; Kahn, C.R.; Roth, J. Phlorizin: a review. Diabetes Metab. Res. Rev., 2005, 21, 31-38.
105. Tsujihara, K.; Hongu, M.; Saito, K.; Kawanishi, H.; Kuriyama, K.; Matsumotu, M.; Oku, A.; Ueta, K.; Tsuda, M.; Saito, A. Na(+)-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives substituted on the B ring. J. Med. Chem., 1999, 42, 5311-5324.
106. Katsuno, K.; Fujimori, Y.; Takemura, Y.; Hiratochi, M.; Itoh, F.; Komatsu, Y.; Fujikura, H.; Isaji, M. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J. Pharmacol. Exp. Ther., 2007, 320, 323-330.
107. Isaji, M. Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney Int. Suppl., 2011, 79, S14-19.
108. Meng, M.; Ellsworth, B.A.; Nirschl, A.A.; McCann, P.J.; Patel, M.; Girotra, R.N.; Wu, G.; Sher, P.M.; Morrison, E.P.; Biller, S.A.; Zahler, R.; Deshpande, P.P.; Pullockaran, A.; Hagan, D.L.; Morgan, N.; Taylor, J.R.; Obermeier, M.T.; Humphreys, W.G.; Khanna, A.; Discenza, L.; Robertson, J.M.; Wang, A.; Han, S.; Wetterau, J.R.; Janovitz, E.B.; Flint, O.P.; Whaley, J.M.; Washburn, W.N. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2008, 51, 1145-1149.
109. Nomura, S.; Sakamaki, S.; Hongu, M.; Kawanishi, E.; Koga, Y.; Sakamoto, T.; Yamamoto, Y.; Ueta, K.; Kimata, H.; Nakayama, K.; Tsuda-Tsukimoto, M. Discovery of canagliflozin, a novel Cglucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J. Med. Chem., 2010, 53, 6355-6360.
110. Li, P.; Zhu, W.L.; Chen, K.X. Advances in the study of berberine and its derivatives. Acta Pharm. Sin., 2008, 43, 773-787.
111. Zhou, Y.; Cao, S.; Wang, Y.; Xu, P.; Yan, J.; Bin, W.; Qiu, F.; Kang, N. Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells. Fitoterapia, 2014, 92, 230-237.
112. Li, Y.H.; Li, Y.; Yang, P.; Kong, W.J.; You, X.F.; Ren, G.; Deng, H.B.; Wang, Y.M.; Wang, Y.X.; Jiang, J.D.; Song, D.Q. Design, synthesis, and cholesterol-lowering efficacy for prodrugs of berberrubine. Bioorg. Med. Chem., 2010, 18, 6422-6428.